Conference presentations

Export 89 results:
[ Author(Desc)] Title Type Year
Filters: Type is Conference Proceedings  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Ambrose JC, Foster GM, Fearnhill E, Leigh Brown A, Porter K, Mackie N, Fidler S, Geretti AM, On behalf of the UK Register of HIV Seroconverters and the UK HIV Drug Resistance Database.  2011.  The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.
B
Bansi L, Geretti AM, Dunn DT, Sabin CA, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.
Barber TJ, Harrison LJ, Asboe D, Williams I, Bansi L, Pillay D, Dunn DT.  2011.  Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.
K Bouzidi E, White E, Mbisa JL, Phillips AN, Mackie N, Pozniak A, Dunn DT.  2014.  Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.
Boyd K, Walker S, Dunn DT, Judd A, Pillay D, Menson E, Tudor-Williams G, Gibb DM.  2010.  The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.
Bradshaw D, Dolling D, Booth C, Nelson M, Dunn DT, Asboe D.  2012.  How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Bulteel N, Nelson M, Churchill D, Sabin CA.  2012.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort. 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Byrne L, Thorne C, Tookey P, Tostevin A, Dunn DT, Chau C, Delpech V.  2015.  Antiretroviral drug resistance in pregnant women living with HIV in England and Wales: Preliminary results from the matching of three national HIV surveillance databases. British HIV Association Conference (BHIVA) 2015.
C
Cambiano V, Castro H, Chadwick D, Smit E, Geretti AM, Dunn DT, Phillips AN, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2014.  Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
Castro H, Dunn DT, Cane P A, Asboe D, Cambiano V, Phillips AN, Pillay D, UK HIV Drug Resistance Database.  2012.  Persistence of transmitted HIV drug resistance mutations. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A167.
Chilton DN, Harrison LJ, Green H, Lattimore S, Delpech V, Pillay D.  2008.  Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.
Cozzi-Lepri A, Dunn DT, Pillay D, Sabin CA, Fearnhill E, Phillips AN, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Croxford S, Chau C, Skingsley A, Tostevin A, Dolling D, Delpech V, UK HIV Drug Resistance Database.  2014.  National audit of baseline HIV resistance testing among newly-diagnosed adults. Third Joint Conference of BHIVA and BASHH, 1-14 April 2014.
D
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Williams I, Geretti AM, Mackie N, Pillay D, Dunn DT et al..  2012.  Has a Limit to the Decline in Transmitted Drug Resistance Been Reached? Evidence from a Large Surveillance Study of UK-acquired Infections 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Dolling D, Nelson M, Schwenk A, Churchill D, Pillay D, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2013.  Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Dunn DT, Green H, Matthias R, Woodburn P, Gifford RJM, Chrystie I, Zuckerman M., Geretti AM, Loveday C, Clark J et al..  2004.  Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Dunn DT, UK HIV Drug Resistance Database.  2005.  Patterns of thymidine analogue mutations (TAMS) in samples sent for routine HIV drug resistance testing. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Dunn DT, Green H, Fearnhill E.  2007.  Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.
E
Easterbrook P, Welz T, UK HIV Drug Resistance Database.  2006.  Impact of HIV-1 subtype on genotypic resistance to protease inhibitors in the United Kingdom. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006.
F
Foster GM, Ambrose JC, Hue S, Conibear T, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2011.  Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.